[go: up one dir, main page]

MX2008010222A - Antibioticos nebulizados para terapia de inhalacion. - Google Patents

Antibioticos nebulizados para terapia de inhalacion.

Info

Publication number
MX2008010222A
MX2008010222A MX2008010222A MX2008010222A MX2008010222A MX 2008010222 A MX2008010222 A MX 2008010222A MX 2008010222 A MX2008010222 A MX 2008010222A MX 2008010222 A MX2008010222 A MX 2008010222A MX 2008010222 A MX2008010222 A MX 2008010222A
Authority
MX
Mexico
Prior art keywords
antibiotics
nebulised
aerosols
inhalation therapy
sinunasal
Prior art date
Application number
MX2008010222A
Other languages
English (en)
Inventor
Manfred Keller
Aslihan Akkar
Original Assignee
Pari Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pari Pharma Gmbh filed Critical Pari Pharma Gmbh
Publication of MX2008010222A publication Critical patent/MX2008010222A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nanotechnology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona aerosoles farmacéuticos que son útiles para la prevención o tratamiento de enfermedades infecciosas de vías respiratorias, tales como pulmones, bronquios o cavidades sinunasales. Los aerosoles comprenden un agente activo seleccionado del grupo de antibióticos quinolonas. También se describen composiciones líquidas y sólidos adecuados para ser convertidas en aerosoles, y equipos que comprenden dichas composiciones.
MX2008010222A 2006-02-10 2007-02-08 Antibioticos nebulizados para terapia de inhalacion. MX2008010222A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06002734 2006-02-10
PCT/EP2007/001080 WO2007090646A1 (en) 2006-02-10 2007-02-08 Nebulised antibiotics for inhalation therapy

Publications (1)

Publication Number Publication Date
MX2008010222A true MX2008010222A (es) 2008-10-17

Family

ID=36607472

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008010222A MX2008010222A (es) 2006-02-10 2007-02-08 Antibioticos nebulizados para terapia de inhalacion.

Country Status (19)

Country Link
US (1) US20090025713A1 (es)
EP (1) EP1991201B1 (es)
JP (1) JP2009526003A (es)
CN (1) CN101389313A (es)
AU (1) AU2007213983B2 (es)
BR (1) BRPI0707641A2 (es)
CA (1) CA2641827A1 (es)
CY (1) CY1120284T1 (es)
DK (1) DK1991201T3 (es)
ES (1) ES2671342T3 (es)
HU (1) HUE037773T2 (es)
LT (1) LT1991201T (es)
MX (1) MX2008010222A (es)
PL (1) PL1991201T3 (es)
PT (1) PT1991201T (es)
RU (1) RU2008136460A (es)
SI (1) SI1991201T1 (es)
TR (1) TR201807714T4 (es)
WO (1) WO2007090646A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8545463B2 (en) * 2003-05-20 2013-10-01 Optimyst Systems Inc. Ophthalmic fluid reservoir assembly for use with an ophthalmic fluid delivery device
EP1624938B1 (en) * 2003-05-20 2011-03-16 James F. Collins Ophthalmic drug delivery system
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8524735B2 (en) * 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
GB0602980D0 (en) 2006-02-14 2006-03-29 Optinose As Delivery device and method
EP2030644A1 (en) * 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
AU2008310734B2 (en) * 2007-10-10 2014-06-05 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
US20090212133A1 (en) * 2008-01-25 2009-08-27 Collins Jr James F Ophthalmic fluid delivery device and method of operation
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2257172A4 (en) * 2008-02-26 2013-07-03 Elevation Pharmaceuticals Inc METHOD AND SYSTEM FOR TREATING CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY USING ANTICHOLINERGIC DELIVERY USING NEBULIZATION
EP2346509B1 (en) * 2008-10-07 2020-05-13 Horizon Orphan LLC Inhalation of levofloxacin for reducing lung inflammation
CA2739897C (en) 2008-10-07 2017-10-03 Mpex Pharmaceuticals, Inc. Aerosol fluoroquinolone formulations for improved pharmacokinetics
WO2010048341A1 (en) 2008-10-22 2010-04-29 Inspire Pharmaceuticals, Inc. Method for treating cystic fibrosis
CA2752296C (en) * 2009-02-18 2018-09-11 Aradigm Corporation Ph-modulated formulations for pulmonary delivery
ES2457442T3 (es) * 2009-05-08 2014-04-25 Pari Pharma Gmbh Formulaciones farmacéuticas concentradas estabilizadoras de los mastocitos
KR20120103561A (ko) * 2009-08-19 2012-09-19 엠펙스 파마슈티컬즈, 인코포레이티드 만성 폐쇄성 폐 질병을 처치하는 에어로졸화된 항생제의 사용
AU2015275224C1 (en) * 2009-09-04 2017-11-16 Horizon Therapeutics U.S. Holding Llc Use of aerosolized levofloxacin for treating cystic fibrosis
RU2015130524A (ru) * 2009-09-04 2018-12-21 Раптор Фармасьютикалз Инк. Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза
CN102770141A (zh) * 2010-02-25 2012-11-07 参天制药株式会社 含有左氧氟沙星或其盐、或者它们的溶剂合物的眼感染症治疗用滴眼剂，眼感染症的治疗方法，左氧氟沙星或其盐、或者它们的溶剂合物及其使用
RU2597842C2 (ru) * 2010-07-12 2016-09-20 Кселлия Фармасьютикалз Апс Лечение легочных инфекций с помощью введения тобрамицина путем аэролизации
MX339173B (es) 2010-07-15 2016-05-12 Corinthian Ophthalmic Inc Dispositivo generador de gotas.
CN103124541B (zh) 2010-07-15 2015-09-30 艾诺维亚股份有限公司 眼药物递送
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
EA201390121A8 (ru) 2010-07-15 2014-02-28 Коринтиан Офтэлмик, Инк. Способ и система для выполнения дистанционного лечения и контроля
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
EP2717855A4 (en) 2011-06-07 2014-11-12 Parion Sciences Inc PROCESSING METHODS
EP2790620A1 (en) 2011-12-12 2014-10-22 Corinthian Ophthalmic, Inc. High modulus polymeric ejector mechanism, ejector device, and methods of use
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
US10064583B2 (en) 2013-08-07 2018-09-04 Covidien Lp Detection of expiratory airflow limitation in ventilated patient
JP2016535774A (ja) * 2013-10-30 2016-11-17 インスピリックス, インコーポレーテッドInspirx, Inc. 多剤耐性結核治療のための噴霧吸入による免疫化学療法
CN106456595A (zh) * 2014-02-10 2017-02-22 帕塔拉制药有限责任公司 用于系统性病症的肥大细胞稳定剂治疗
CN106535889A (zh) 2014-02-10 2017-03-22 帕塔拉制药有限责任公司 用于治疗肺疾病的肥大细胞稳定剂
EP4079417A1 (en) 2015-06-10 2022-10-26 Stamford Devices Limited Aerosol generation
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
DK3463281T3 (da) * 2016-05-31 2022-09-26 Spexis Ag Beta-hårnåls peptidomimetic med elastase hæmmende aktivitet og aerosol doseringsformer heraf
GB201611639D0 (en) 2016-07-04 2016-08-17 Ockham Biotech Ltd Delivery device and formulation
US20190231686A1 (en) * 2016-07-16 2019-08-01 Lauranell Harrison BURCH Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
CN110139646A (zh) 2016-08-31 2019-08-16 瑞思皮万特科学有限责任公司 用于治疗由特发性肺纤维化引起的慢性咳嗽的色甘酸组合物
CN107669636A (zh) * 2016-09-30 2018-02-09 青岛大学 一种氨溴索喷雾剂
EP3522983A4 (en) 2016-10-07 2020-06-03 Respivant Sciences GmbH CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS
SG11201911895XA (en) 2017-06-10 2020-01-30 Eyenovia Inc Methods and devices for handling a fluid and delivering the fluid to the eye
CN109260180A (zh) * 2017-07-17 2019-01-25 北京盈科瑞创新药物研究有限公司 一种盐酸莫西沙星雾化吸入用溶液制剂及其制备方法
CN109419785A (zh) * 2017-08-31 2019-03-05 正大青春宝药业有限公司 一种鱼腥草提取物制剂及其应用
IT201900006104A1 (it) * 2019-04-18 2020-10-18 S I I T S R L Servizio Int Imballaggi Termosaldanti Metodo di preparazione di un prodotto a base di chitosano
CN112569211A (zh) * 2019-09-27 2021-03-30 盈科瑞（天津）创新医药研究有限公司 一种吸入用加替沙星溶液及其制备方法
EP4072483A4 (en) 2019-12-11 2024-02-07 Eyenovia, Inc. Systems and devices for delivering fluids to the eye and methods of use
CN114948914B (zh) * 2022-06-30 2024-04-02 北京新领先医药科技发展有限公司 一种盐酸莫西沙星雾化吸入用溶液剂及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0868183T1 (en) * 1995-12-21 2002-04-30 Pfizer Inc. Injectable quinolone formulations
EP1014943B1 (de) * 1997-02-05 2002-06-19 Jago Research Ag Medizinische aerosolformulierungen
CN1158996C (zh) * 1998-07-24 2004-07-28 杰格研究股份公司 药用气溶胶制剂
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
US6070575A (en) * 1998-11-16 2000-06-06 Aradigm Corporation Aerosol-forming porous membrane with certain pore structure
US6397838B1 (en) * 1998-12-23 2002-06-04 Battelle Pulmonary Therapeutics, Inc. Pulmonary aerosol delivery device and method
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
KR100702878B1 (ko) * 1999-10-29 2007-04-04 넥타르 테라퓨틱스 개선된 분산성을 갖는 건조 분말 조성물
US6962151B1 (en) * 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
US6550472B2 (en) * 2001-03-16 2003-04-22 Aerogen, Inc. Devices and methods for nebulizing fluids using flow directors
ES2474600T3 (es) * 2001-07-31 2014-07-09 Philip Morris Products S.A. Método y aparato para generar un material volatilizado
JP2005508220A (ja) * 2001-10-24 2005-03-31 パーリ・ゲーエムベーハー 薬用組成物調製用具
US6702997B2 (en) * 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
AU2003225689B2 (en) * 2002-03-05 2009-03-26 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
DE10239321B3 (de) * 2002-08-27 2004-04-08 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
WO2004110493A2 (en) * 2003-05-30 2004-12-23 Alza Corporation Method of pulmonary administration of an agent
AU2004291172B2 (en) * 2003-11-17 2010-11-11 Novartis Ag Efficient introduction of an aerosol into a ventilator circuit
RU2006127432A (ru) * 2003-12-31 2008-02-10 Сайдекс, Инк. (Us) Ингаляционная композиция, содержащая сульфоалкиловый эфир циклодекстрина и кортикостероид, полученная из единичной дозы суспензии
CA2559208A1 (en) * 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
KR101538677B1 (ko) * 2005-05-18 2015-07-22 엠펙스 파마슈티컬즈, 인코포레이티드 에어로졸화된 플루오로퀴놀론 및 이의 용도

Also Published As

Publication number Publication date
BRPI0707641A2 (pt) 2011-05-10
EP1991201B1 (en) 2018-03-28
EP1991201A1 (en) 2008-11-19
HUE037773T2 (hu) 2018-09-28
AU2007213983B2 (en) 2012-09-20
CN101389313A (zh) 2009-03-18
ES2671342T3 (es) 2018-06-06
TR201807714T4 (tr) 2018-06-21
US20090025713A1 (en) 2009-01-29
SI1991201T1 (en) 2018-08-31
JP2009526003A (ja) 2009-07-16
PT1991201T (pt) 2018-06-12
CA2641827A1 (en) 2007-08-16
LT1991201T (lt) 2018-07-25
RU2008136460A (ru) 2010-03-20
PL1991201T3 (pl) 2018-09-28
AU2007213983A1 (en) 2007-08-16
CY1120284T1 (el) 2019-07-10
WO2007090646A1 (en) 2007-08-16
DK1991201T3 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
MX2008010222A (es) Antibioticos nebulizados para terapia de inhalacion.
IL225529A0 (en) Fosfomycin/aminoglycoside combination in spray form for the treatment of bacterial infections of the respiratory tract
CL2007002099A1 (es) Compuestos derivados de 3h-espiro(1-benzofuran-2,4'-piperidina); proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades respiratorias, tales como epoc y asma.
UA95199C2 (en) Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
MX359219B (es) Fluoroquinolonas aerosolizadas y sus usos.
MX2010002498A (es) Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.
TNSN08079A1 (en) Pharmaceutical compositions for the treatment of inner ear disorders
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
IL193074A0 (en) Stable pharmaceutical formulations of montelukast sodium
WO2007087548A3 (en) Chemical compounds
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
HK1203815A1 (en) Pharmaceutical compositions and methods for their preparation
TR201000733A2 (tr) Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
PT1610787E (pt) Associação sinérgica compreendendo roflumilast e um agente anticolinérgico seleccionado de sais de tiotrópio para o tratamento de doenças respiratórias
WO2014064652A3 (en) Stable pharmaceutical composition of peginterferon alpha-2b
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
MXPA05008407A (es) Tratamiento de enfermedades bacterianas de los organos respiratorios aplicando localmente fluoroquinolonas.
WO2011113000A8 (en) Novel ester containing compositions and methods
WO2008004100A3 (en) Therapeutic compounds
MX2010004529A (es) Composiciones de inhalacion que comprenden acido montelukast y un inhibidor de fosfodiesterasa-4 o un corticoesteroide inhalado.
AU2003290127A1 (en) 4-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level
ATE353231T1 (de) Pharmazeutische zusammensetzungen
ITMI20060158U1 (it) Apparecchiatura per la somministrazione di ossigeno o di aria addizionata da ossigeno,per terapie respiratorie.
WO2008039894A3 (en) Atorvastatin pharmaceutical compositions

Legal Events

Date Code Title Description
FA Abandonment or withdrawal